MedTrace Logo

Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer

NCT01741116 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2021-02-18

No results posted yet for this study

Summary

The aim of this study is to evaluate efficacy and safety of Dovitinib(TKI258) in patients with castration resistant prostate cancer after failure of docetaxel-based chemotherapy. Further correlative study for metabolic response using PET image and change in serum fibroblast growth factor 23(FGF23) will be conducted.

Conditions

  • Hormone Refractory Prostate Cancer

Interventions

DRUG

TKI258

Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal

Sponsors & Collaborators

  • Korean Cancer Study Group

    lead OTHER

Principal Investigators

  • Kyong Hwa Park, MD, phD · Korea University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-12-31
Completion
2016-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01741116 on ClinicalTrials.gov